Moreover, 15% of them were taking LAMA or LABA therapies in combination ... approval and launch of the company's lead drug candidate into the large COPD market in late 2023 or 2024.

Verona filed for approval of ensifentrine last year on the strength of clinical data showing significant improvements in lung function with the drug in COPD patients, as well as a reduction in ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

There are certain risk factors for COPD, including obesity and having type 2 diabetes. A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications ...

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance ...

A multimodal, digital community-based intervention was feasible and decreased illness-related distress in treating patients ...

The Centre has provided a Z-category armed protection cover to Tibetan spiritual leader Dalai Lama in view of potential security threats to him, official sources said on Thursday. The Union home ...

RAs, and DPP-4is may offer benefits for patients with COPD, but clinical evidence comparing their effectiveness in reducing ...

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. Many ...